Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of an underwritten public offering of 15,925,000 ordinary shares at a public offering price of $11.00 per share. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be approximately $175 million. The offering is expected to close on January 22, 2024, subject to customary closing conditions. In addition, Immatics has granted the underwriters a 30-day option to purchase up to 2,388,750 additional shares at the public offering price, less the underwriting discount. Jefferies, BofA Securities and Leerink Partners are acting as joint book-running managers for the offering. A registration statement relating to the securities has been filed with the U.S. Securities and Exchange Commission (the “SEC”) and was declared effective on August 9, 2021. The offering is being made only by means of a prospectus supplement and accompanying prospectus. When available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained free of charge from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 821-7388, email: Prospectus_Department@Jefferies.com; BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, telephone: (800) 294-1322, email: dg.prospectus_requests@bofa.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, telephone: (800) 808-7525, ext. 6105, email: syndicate@leerink.com. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended. - END - About Immatics Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer. Forward-Looking Statements Certain statements in this press release may be considered forward-looking statements, including statements regarding the securities offering. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in filings with the SEC. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Immatics undertakes no duty to update these forward-looking statements. For more information, please contact: Media Trophic Communications Phone: +49 171 3512733 immatics@trophic.eu Investor Relations Sabrina Schecher, Ph.D. Senior Director, Investor Relations Phone: +49 89 262002433 InvestorRelations@immatics.com

AMSilk, a global leader in advanced materials made from spider silk-based proteins, and 21st.BIO, a leader in bioproduction, today announced that they have joined forces to accelerate the upscaling of AMSilk’s silk protein production to unprecedented levels. As part of the partnership, 21st.BIO has developed a new protein production strain created from highly specialized precision fermented microorganisms, ensuring that AMSilk can meet demand as it increases production from the laboratory to industrial scale. The new strain ensures extracellular expression of silk proteins, enabling manufacturing at unprecedented productivity levels due to higher yield and greater efficiency, thereby reducing production costs. Due to its unique combination of strength and flexibility, spider silk is the gold standard of bio industrial materials. AMSilk’s spider silk-based proteins are wholly biodegradable and biocompatible. Based on a renewable plant based feedstock, AMSilk fibers do not contain any substances of animal origin and come with a CO2 greenhouse gas emission reduction of up to 90% and more than 90% less land and water use compared to other protein fibers. Their high-performance qualities enable a wide range of applications in the textile, homecare, biomedical, and automobile industries. The AMSilk x 21st.BIO genesis As one of the world’s first industrial scale suppliers of advanced materials made from spider silk-based proteins, AMSilk has been redefining the performance fiber category since 2015, with applications in footwear and garments, and even interior components for automobiles. With a strong patent portfolio, AMSilk is leading the discovery of performance materials based on spider silk proteins. 21st.BIO benefits from the most advanced precision fermentation technology platform in the industry, with production strains that have been perfected for over 40 years and used in dozens of products on the market today. Working in close collaboration with AMSilk, 21st.BIO’s scientists have developed and optimized new production strains, fermentation and downstream processes to support upscaled production and significantly reduce unit costs. This will enable AMSilk to further broaden its portfolio into different types of fibers and proteins, with applications in the broader mid-market. Gudrun Vogtentanz, Chief Scientific Officer, AMSilk said: “AMSilk’s protein-based products unlock the secrets of spider silk to create engineerable structures and solutions. Through 21st.BIO, we now have access to more efficient production strains, which are a game changer in terms of the efficiency and sustainability of our feedstock. Moving production quantities from kilos to tons brings AMSilk’s technology to the next level. This collaboration with 21st.BIO is key to accelerating time-to-market for AMSilk in the current scale-up phase.” Ulrich Scherbel, Chief Executive Officer, AMSilk commented: “By partnering with 21st.BIO, we are succeeding where so many have struggled, delivering high performance precision fermentation at the right quality and cost parameters, and at a true industrial scale.” 2 Thomas Schmidt, Chief Executive Officer, 21st.BIO added: “We founded 21st.BIO to help companies cross over from interesting innovations at lab scale to reliable industrial biotech production in a timely and risk mitigated way. With spider silk proteins this has been challenging, but AMSilk is the first to be able to achieve that goal and bring spider silk proteins into large scale production. The world needs innovators and category shapers like AMSilk and our job is to help them succeed.” Per Falholt, Chief Scientific Officer, 21st.BIO continued: “We are incredibly proud to support companies like AMSilk. Our partnership has already led to some key milestone achievements, such as the world’s first extracellular expression of spider silk protein, which facilitates processes and enables manufacturing at unprecedented productivity levels. We are confident that within a short time frame, we can achieve a significant reduction in production costs, enabling AMSilk to enter higher value markets.” The potential for spider silk proteins produced using precision fermentation Global bioplastics production will more than triple until 2026, from around 2.4 million tons in 2021 to 7.5 million tons in 2026[1]. There is a rapidly growing need to adopt more environmental-friendly materials. AMSilk is helping to meet this need by using its outstanding proprietary technology platform for large volume proteins, designing and customizing material properties at a molecular level depending on the final application or properties required. AMSilk has developed a wide range of use cases for its silk proteins, from developing the leading spinning process for silk protein fibers, to transforming proteins into silk beads, gels and solutions to unlock the power of their coating effects. AMSilk’s silk protein-based fibers set completely new standards within the apparel industry, offering unbelievably broad performance characteristics, ranging from ultra fineness to extreme strength, making them ideal as premium, low carbon material alternatives. AMSilk has also entered the performance yarn segment with technical yarns for the automotive industry – reflected in its collaboration with Mercedes Benz. AMSilk’s silk protein formulations bring exceptional filming properties to dishwashing and laundry care, providing outstanding performance benefits as a bioshield. [1] Source: World Biopolymers and Bioplastics Innovation Forum | 1st – 2nd March 2023 | Leadvent Group (leadventgrp.com) For more information, please contact: 21st.BIO Mathilde Pinon, Marketing & Business Development Manager m.pinon@21st.BIO AMSilk GmbH Isabel Rosenberger, Senior Manager Marketing & Communications Tel. +49 (0) 151 6106 3269 E-Mail: isabel.rosenberger@amsilk.com Optimum Strategic Communications Nick Bastin, Vici Rabbetts, Katie Flint Tel: +44 (2)03 922 1906 E-mail: amsilk@optimumcomms.com About AMSilk AMSilk is a global leader in advanced materials made from spider silk-based proteins. AMSilk’s spider silk-based proteins are wholly biodegradable and biocompatible. Based on a vegan raw material, they do not contain any substances of animal origin and come with 8x lower CO2 emissions and more than 90% less land and water use than traditional materials. Their high-performance qualities enable a wide range of applications in the textile, homecare, biomedical, and automobile industries. AMSilk’s truly sustainable materials outperform existing, fossil-based products not only through their optimal relationship between performance and positive environmental impact, but also through the adaptability of multiple benefits to a broad range of meaningful applications. AMSilk aims to expand the use of its biobased, biodegradable, recyclable, and biocompatible products, reducing dependence on the natural resources of the planet. The Company has already collaborated with industry-leading global companies and plans to continue partnering with influential worldwide enterprises in its vision to make high performance materials for a sustainable future. About 21st.BIO Founded in 2020, 21st.BIO is headquartered in Copenhagen, Denmark, with a strong scientific and commercial presence in Davis, California. On a mission to support bioindustrial companies globally in upscaling from molecule innovation to large-scale production, 21st.BIO enables its customers to meet market demands, and thereby advance the green transition globally. 21st.BIO focuses on developing industrial production technology for proteins and other molecules of interest for food, materials, and agricultural industries. Established as a fully integrated end-to-end partner, 21st.BIO supports its customers from technical assessment, strain development and optimization, production processes and upscaling, tech transfer to large scale manufacturing and regulatory services.

DieEnergiekoppler GmbH, ein innovatives Software-Unternehmen für Energiemanagement-Lösungen und eine Ausgründung aus zwei renommierten Instituten – dem Institut für Elektrische Energieversorgung und Hochspannungstechnik und dem Institut für Gebäudeenergietechnik - der Technischen Universität Dresden, hat eine Serie A-Finanzierungsrunde erfolgreich abgeschlossen. Im Zuge dieser Runde ist das Osnabrücker Cleantech-Unternehmen ElectroFleet als zusätzlicher strategischer Investor neben den bereits bestehenden Investoren LEAG und TGFS – Technologiegründerfonds Sachsen eingestiegen. Die Finanzierungsrunde sichert die Weiterentwicklung der Produkte und Expansion der Vertriebsaktivitäten von Energiekoppler. Jens Werner, Gründer und Geschäftsführer von DieEnergiekoppler, über die Finanzierungsrunde "Diese Finanzierungsrunde ist ein wichtiger Meilenstein für die weitere Expansion unseres Unternehmens. Dieses Investment ermöglicht es uns, unsere Produkte anhand der Markterfordernisse weiterzuentwickeln, unser Team zu vergrößern und unser Geschäft insgesamt breiter aufzustellen und nachhaltig zu entwickeln. Wir werden nun gezielt unser Team insbesondere in Produktentwicklung und Vertrieb verstärken. Zusätzlich werden Investitionen in Vertrieb und Marketing getätigt, um die Präsenz und Reichweite weiter auszubauen. Wir freuen uns aber besonders über den Einstieg von ElectroFleet als strategischer Investor. Diese Investition stärkt die bestehende strategische Produkt-Partnerschaft zwischen Energiekoppler und ElectroFleet und unterstreicht das gemeinsame Engagement für innovative Energietechnologien im Energiesektor.“ Mark Hellmann Regouby, Gründer und CEO von ElectroFleet, kommentiert die Investition seines Unternehmens „Wir schätzen uns glücklich, gemeinsam mit den anderen Gesellschaftern die weitere Entwicklung von Energiekoppler zu unterstützen. Die Gründer und das Team leisten großartige Arbeit, und wir freuen uns, diesen nächsten Schritt in unserer langfristigen Strategie zur Dekarbonisierung mittelständischer Unternehmen in Deutschland zu gehen. Dies ist unsere erste Investition aus unserem Venture-Fonds, der ElectroFleet Ventures GmbH, mit der wir Technologien und Teams unterstützen, die für die Erfüllung unserer Mission, die Energieprobleme des deutschen Mittelstands zu lösen, unerlässlich sind.“. Robert Klimpke, Head of Innovation bei LEAG, sagt: „Wir sind stolz darauf, unsere bestehende Partnerschaft mit Energiekoppler im Rahmen dieser Finanzierungsrunde zu vertiefen und freuen uns auf die Zusammenarbeit mit ElectroFleet im Kreis der Gesellschafter. Mit dem Abschluss dieser Finanzierungsrunde unterstreichen wir einmal mehr unser anhaltendes Engagement für wegweisende Innovationen im Energiesektor.“ Martin Liebsch, Gruppenleiter Digital Tech / Prokurist, Start-Up Investments bei TGFS, fügt hinzu: „Wir begleiten DieEnergiekoppler GmbH bereits seit einigen Jahren und sind überzeugt, dass die jetzige Finanzierungsrunde das weitere Wachstum des Unternehmens auf eine neue Stufe heben wird. Das strategische Investment durch ElectroFleet zeigt das Vertrauen in die technologische Entwicklung und das Geschäftsmodell des Unternehmens. Diese Partnerschaft stärkt unsere langjährige Unterstützung für innovative Start-ups im Energiesektor und bestätigt uns in unserem Engagement für zukunftsweisende Technologien.“ Die Zusammenarbeit zwischen den drei Investoren und Energiekoppler steht für eine wegweisende Synergie, um innovative Energielösungen und virtuelle Kraftwerke weiterzuentwickeln und den Energiesektor nachhaltig zu gestalten. Über DieEnergiekoppler GmbH DieEnergiekoppler GmbH ist ein Software-as-a-Service-Unternehmen, das mit dem Flexibilitätswerk eine innovative Technologie für die optimale Steuerung dezentraler Energieanlagen in Verbindung mit erneuerbaren Energiesystemen bietet. Das Unternehmen ist eine Ausgründung aus zwei renommierten Instituten der Technischen Universität Dresden, dem Institut für Elektrische Energieversorgung und Hochspannungstechnik und dem Institut für Gebäudeenergietechnik. DieEnergiekoppler GmbH befasst sich insbesondere mit den Herausforderungen konventioneller Vernetzungstechnologien, speziell virtueller Kraftwerke, und fokussiert sich auf die Steigerung der Wirtschaftlichkeit bei der Integration kleinerer Energieanlagen. Ihre innovative Technologie, das „Flexibilitätswerk“, eröffnet neue Perspektiven für virtuelle Kraftwerke, indem es erstmals die wirtschaftliche und anwendungsorientierte Integration von Brennstoffzellen, Wärmepumpen, Photovoltaik-Anlagen und Speichertechnologien ermöglicht. Dadurch wird eine ausgeglichene, sichere Strom- und Wärmeversorgung in unabhängigen regionalen Energiegemeinschaften gewährleistet, einschließlich der Berücksichtigung des Bereichs Elektromobilität. Die hochautomatisierten und technologieoffenen Flexibilitätswerke bieten Energieversorgern, Stadtwerken, Energiegemeinschaften, Vermarktern und Anlagenbetreibern die Möglichkeit, nicht nur Anlagen zu überwachen, sondern diese aktiv vollautomatisiert zu steuern für regionalen Energieausgleich oder börsenpreisoptimiert für zusätzliche Erlöspotentiale im Energiehandel mit uneingeschränkter Anlagengröße. Das Team startete 2018 mit der BMWi-Förderung EXIST-Forschungstransfer und erhielt im Herbst 2019 eine Platzierung als eines von neun Startups im SpinLab Accelerator-Programm. Im November 2021 schloss Energiekoppler eine erste Finanzierungsrunde durch die LEAG und den Technologiegründerfonds Sachsen (TGFS) ab. Im November 2023 schloss das Unternehmen eine Serie-A-Finanzierungsrunde mit Beteiligung der LEAG, TGFS und ElectroFleet erfolgreich ab. Weitere Informationen unter www.dieenergiekoppler.com.